Harvard Total Assets vs Long Term Investments Analysis
HBIO Stock | USD 2.24 0.03 1.32% |
Harvard Bioscience financial indicator trend analysis is much more than just examining Harvard Bioscience latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Harvard Bioscience is a good investment. Please check the relationship between Harvard Bioscience Total Assets and its Long Term Investments accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.
Total Assets vs Long Term Investments
Total Assets vs Long Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Harvard Bioscience Total Assets account and Long Term Investments. At this time, the significance of the direction appears to have no relationship.
The correlation between Harvard Bioscience's Total Assets and Long Term Investments is 0.0. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Long Term Investments in the same time period over historical financial statements of Harvard Bioscience, assuming nothing else is changed. The correlation between historical values of Harvard Bioscience's Total Assets and Long Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Harvard Bioscience are associated (or correlated) with its Long Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Investments has no effect on the direction of Total Assets i.e., Harvard Bioscience's Total Assets and Long Term Investments go up and down completely randomly.
Correlation Coefficient | 0.0 |
Relationship Direction | Flat |
Relationship Strength | Insignificant |
Total Assets
Total assets refers to the total amount of Harvard Bioscience assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Harvard Bioscience books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Long Term Investments
Long Term Investments is an item on the asset side of Harvard Bioscience balance sheet that represents investments Harvard Bioscience intends to hold for over a year. Harvard Bioscience long term investments may include different instruments such as stocks, bonds, real estate and cash.Most indicators from Harvard Bioscience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Harvard Bioscience current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.At this time, Harvard Bioscience's Selling General Administrative is very stable compared to the past year. As of the 26th of November 2024, Tax Provision is likely to grow to about 1.1 M, while Discontinued Operations is likely to drop about 1.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 67.7M | 60.8M | 60.9M | 48.3M | Total Revenue | 118.9M | 113.3M | 112.3M | 96.8M |
Harvard Bioscience fundamental ratios Correlations
Click cells to compare fundamentals
Harvard Bioscience Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Harvard Bioscience fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 164.9M | 156.3M | 162.3M | 145.4M | 137.4M | 124.6M | |
Total Stockholder Equity | 81.7M | 76.7M | 83.4M | 72.2M | 73.1M | 82.7M | |
Net Debt | 45.5M | 39.7M | 40.5M | 42.3M | 38.5M | 40.4M | |
Cash | 8.3M | 8.3M | 7.8M | 4.5M | 4.3M | 4.1M | |
Other Assets | 2.3M | 8.9M | 12.3M | 7.8M | 8.9M | 5.2M | |
Cash And Short Term Investments | 8.3M | 8.3M | 7.8M | 4.5M | 4.3M | 4.1M | |
Common Stock Shares Outstanding | 37.8M | 38.6M | 40.3M | 41.4M | 42.4M | 33.1M | |
Liabilities And Stockholders Equity | 164.9M | 156.3M | 162.3M | 145.4M | 137.4M | 124.6M | |
Other Stockholder Equity | 218.5M | 221.7M | 225.7M | 229.0M | 232.4M | 193.5M | |
Total Liab | 83.2M | 79.6M | 78.9M | 73.1M | 64.3M | 41.9M | |
Total Current Assets | 53.6M | 51.7M | 61.6M | 51.1M | 49.0M | 53.5M | |
Short Long Term Debt Total | 53.8M | 48.0M | 48.3M | 46.8M | 42.8M | 22.7M | |
Other Current Liab | 9.1M | 7.2M | 10.5M | 7.5M | 12.3M | 6.2M | |
Total Current Liabilities | 25.3M | 21.1M | 25.3M | 23.2M | 26.5M | 17.5M | |
Property Plant And Equipment Net | 4.8M | 4.0M | 3.4M | 3.4M | 8.8M | 4.9M | |
Retained Earnings | (124.6M) | (132.4M) | (132.7M) | (142.2M) | (145.6M) | (152.9M) | |
Accounts Payable | 5.3M | 6.0M | 4.9M | 6.4M | 5.6M | 5.7M | |
Non Current Assets Total | 111.3M | 104.6M | 100.8M | 94.2M | 88.3M | 73.6M | |
Non Currrent Assets Other | 10.7M | 8.9M | 12.3M | 13.6M | 6.5M | 4.1M | |
Net Receivables | 20.7M | 17.8M | 21.8M | 16.7M | 16.1M | 18.5M | |
Common Stock Total Equity | 438K | 444K | 452K | 454K | 522.1K | 407.4K | |
Non Current Liabilities Total | 57.9M | 58.5M | 53.6M | 49.9M | 37.8M | 25.8M | |
Inventory | 22.1M | 22.3M | 27.6M | 26.4M | 24.7M | 19.3M | |
Other Current Assets | 2.5M | 3.4M | 4.3M | 3.5M | 3.9M | 6.2M | |
Property Plant And Equipment Gross | 13.2M | 11.7M | 3.4M | 24.0M | 23.1M | 24.3M | |
Accumulated Other Comprehensive Income | (12.7M) | (13.1M) | (10.0M) | (15.1M) | (14.2M) | (13.5M) | |
Short Term Debt | 6.9M | 3.8M | 5.4M | 5.9M | 8.7M | 9.1M | |
Intangible Assets | 38.4M | 33.2M | 27.4M | 21.0M | 16.0M | 21.5M | |
Common Stock | 438K | 444K | 452K | 454K | 434K | 410.2K | |
Long Term Debt | 46.9M | 46.3M | 45.1M | 43.0M | 30.7M | 20.7M | |
Good Will | 57.4M | 58.6M | 57.7M | 56.3M | 57.1M | 46.4M | |
Property Plant Equipment | 4.8M | 4.0M | 3.4M | 3.4M | 3.0M | 3.5M | |
Current Deferred Revenue | 3.9M | 3.8M | 4.3M | 3.4M | 7.7M | 8.1M | |
Other Liab | 2.1M | 12.2M | 8.5M | 1.6M | 1.8M | 1.7M | |
Net Tangible Assets | 24.3M | (15.1M) | 83.4M | 72.2M | 65.0M | 68.2M | |
Retained Earnings Total Equity | (124.6M) | (132.4M) | (132.7M) | (142.2M) | (128.0M) | (134.4M) | |
Long Term Debt Total | 9.0M | 58.8M | 46.9M | 46.3M | 53.2M | 30.0M | |
Capital Surpluse | 229.2M | 232.4M | 225.7M | 229.0M | 263.4M | 239.3M | |
Deferred Long Term Liab | 2.3M | 2.0M | 1.9M | 590K | 678.5K | 644.6K |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.33) | Revenue Per Share 2.258 | Quarterly Revenue Growth (0.13) | Return On Assets (0.02) |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.